128 related articles for article (PubMed ID: 32078355)
21. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
[TBL] [Abstract][Full Text] [Related]
22. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
Berry ARW; Finlayson TL; Mellis LM; Urada LA
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
Monico LB; Gryczynski J; Mitchell SG; Schwartz RP; O'Grady KE; Jaffe JH
J Subst Abuse Treat; 2015 Oct; 57():89-95. PubMed ID: 25986647
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013-2017.
Nguemeni Tiako MJ; Friedman A; Culhane J; South E; Meisel ZF
Obstet Gynecol; 2021 Apr; 137(4):687-694. PubMed ID: 33706349
[TBL] [Abstract][Full Text] [Related]
25. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
[TBL] [Abstract][Full Text] [Related]
26. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
[TBL] [Abstract][Full Text] [Related]
27. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
28. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
Haddad MS; Zelenev A; Altice FL
J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
[TBL] [Abstract][Full Text] [Related]
30. A novel community-based buprenorphine program: client description and initial outcomes.
Daniels AM; Salisbury-Afshar E; Hoffberg A; Agus D; Fingerhood MI
J Addict Med; 2014; 8(1):40-6. PubMed ID: 24394496
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
32. Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.
Pytell JD; Fojo AT; Keruly JC; Snow LN; Falade-Nwulia O; Moore RD; Chander G; Lesko CR
Addict Sci Clin Pract; 2023 Sep; 18(1):51. PubMed ID: 37660116
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
34. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.
Weintraub E; Greenblatt AD; Chang J; Himelhoch S; Welsh C
Am J Addict; 2018 Dec; 27(8):612-617. PubMed ID: 30265425
[TBL] [Abstract][Full Text] [Related]
35. Predictors of Family Medicine Patient Retention in Opioid Medication-Assisted Treatment.
Justesen K; A Hooker S; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
J Am Board Fam Med; 2020; 33(6):848-857. PubMed ID: 33219064
[TBL] [Abstract][Full Text] [Related]
36. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
37. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
Khan A; Khan Q; Kolb E
J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
[TBL] [Abstract][Full Text] [Related]
38. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
39. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
